摘要
目的探析舒洛地特联合非奈利酮治疗糖尿病肾病(DKD)的临床效果。方法回顾性采集2022年8月至2024年2月濮阳市人民医院收治的92例DKD患者资料,所有患者均接受常规基础治疗,其中46例接受舒洛地特胶囊治疗的患者纳入对照组,46例接受舒洛地特联合非奈利酮片治疗的患者纳入观察组,持续治疗8周。对比两组治疗前后血清炎症因子、血管内皮指标、肾功能,统计两组临床疗效、治疗期间不良反应发生情况。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,两组患者血清白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、血管内皮生长因子(VEGF)、血清内皮素-1(ET-1)、血肌酐(Scr)、尿素氮(BUN)、半胱氨酸蛋白酶抑制剂C(Cys C)水平均较治疗前降低,且观察组上述指标水平均低于对照组(P<0.05)。治疗期间,两组均未发生药物相关不良反应。结论非奈利酮联合舒洛地特治疗DKD可减轻患者炎症水平,促进内皮功能与肾功能改善,整体效果更好,且不增加不良反应,安全可靠。
Objective To explore the clinical efficacy of sulodemide combined with non-nalidone in the treatment of diabetic kidney disease(DKD).Methods A retrospective analysis was conducted on the data of 92 patients with diabetic kidney disease(DKD)admitted to Puyang People’s Hospital from August 2022 to February 2024.All patients received routine basic treatment,with 46 patients received treatment with sulodemide capsules included in the control group and 46 patients received treatment with sulodemide combined with non-nalidone tablets included in the observation group.The treatment lasted for 8 weeks.The serum inflammatory factors,vascular endothelial indicators and renal function were compared before and after treatment between two groups,and the clinical efficacy and incidence of adverse reactions were calculated during treatment.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of serum interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),vascular endothelial growth factor(VEGF),endothelin-1(ET-1),serum creatinine(Scr),blood urea nitrogen(BUN),cystatin C(Cys C)in both groups of patients decreased compared to before treatment,and the levels of these indicators in the observation group were lower than those the control group(P<0.05).During the treatment period,neither group experienced any drug-related adverse reactions.Conclusion The combination of non-nalidone and sulodemide in the treatment of DKD is more conducive to reducing inflammation levels in patients,promoting improvement in endothelial and renal function,and has a better overall therapeutic effect without increasing adverse reactions,making it safe and reliable.
作者
贾建设
刘莎莎
JIA Jianshe;LIU Shasha(Department of Nephrology,Puyang People’s Hospital,Puyang 457000,China)
出处
《河南医学研究》
2025年第17期3196-3199,共4页
Henan Medical Research
关键词
糖尿病肾病
舒洛地特
非奈利酮
炎症
内皮功能
肾功能
diabetic kidney disease
sulodemide
non-nalidone
inflammation
endothelial function
renal function
